« Return to News | R&D Trends | Drug Sponsors

Biogen Idec announces 2012 goals

Wednesday, January 11, 2012 11:15 AM

Growing its leadership position in multiple sclerosis (MS), advancing its late-state pipeline, leveraging R&D capabilities to grow its early-stage pipeline and preparing for potential launches of new high-impact therapies are among Biogen Idec’s recently announced 2012 strategic priorities.

To grow its leadership position in MS, Biogen Idec plans to advance its Avonex franchise, expand Fampyra’s European footprint through additional launches and boost Tysabri sales by better identifying patients at risk of side effects.

Advancing Biogen Idec’s late-stage pipeline will be achieved by continuing to advance the daclizumb phase III program in MS, as well as delivering the data readout from the first phase III trial of dexpramipexole in ALS by year-end.

Biogen Idec said it hopes to grow its early-state pipeline by building world-class scientific teams in core therapeutic areas; advancing the company’s internal early-state pipeline programs; advancing existing collaborations (e.g., Porola Pharmaceuticals, Isis Pharmaceuticals); entering into new collaborations in neurology, immunology and hemophelia; continuing to focus its research and early discovery efforts and increasing its emphasis on translational research (e.g., biomarker and imaging technologies).

Through its joint venture with Samsung, Biogen Idec said it hopes to leverage its expertise and capabilities in protein engineering, cell line development and recombinant biologics manufacturing to position the company to participate in the emerging market for biosimilars.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.